This announcement is a separate document:
復宏漢霖：自願公告 - 注射用HLX43（靶向PD-L1抗體－新型DNA拓撲異構酶I抑制劑偶聯藥物）單藥或聯合治療晚期╱ 轉移性實體瘤的1b/2期臨床試驗申請獲國家藥品監督管理局批准
HENLIUS: VOLUNTARY ANNOUNCEMENT - APPLICATION FOR PHASE 1B/2 CLINICAL TRIAL OF HLX43FOR INJECTION (ANTIBODY-DRUG CONJUGATE TARGETINGPD-L1 WITH NOVEL DNA TOPOISOMERASE I INHIBITOR)FOR THE MONOTHERAPY OR COMBINATION THERAPYOF ADVANCE/METASTATIC SOLID TUMOURS WAS APPR
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated